Lumos Labs, the company behind the popular Lumosity “Brain Training” program, is agreeing to pay $2 million to settle deceptive advertising claims brought by the Federal Trade Commission.
“Lumosity preyed on consumers’ fears about age-related cognitive decline, suggesting their games could stave off memory loss, dementia, and even Alzheimer’s disease,” Jessica Rich, director of the FTC’s Bureau of Consumer Protection, said in a statement. “But Lumosity simply did not have the science to back up its ads.”
The FTC charged in its complaint (PDF) that Lumosity offered dozens of online or mobile games designed to train specific areas of the brain. The company claimed in its massive advertising campaign that the training would help customers reach their “full potential in every aspect of life,” such as in school, at work, and in sports, and that it would protect against dementia and Alzheimer’s disease. Among other things, the company also claimed that the training could help customers reduce the side effects of chemotherapy. Subscription prices ranged from $14.95 a month to $299.95 for a lifetime membership, the FTC said.
Read 4 remaining paragraphs | Comments